Skip to content
DataLookout
Menu

NCT07543120

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words
    • Trial sites expanded: 25 → 46 locations
    • Primary completion date: May 31, 2031 to May 7, 2031
    • Study completion date: Nov 30, 2031 to Nov 7, 2031
  2. Minor Trial sites expanded: 13 → 25 locationsv4
  3. Minor Trial sites expanded: 7 → 13 locationsv3
  4. Notable Recruitment opened
    • Trial sites expanded: 0 → 7 locations
    • Start date changed from estimate of May 1, 2026 to May 7, 2026
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with AEs
Timeframe: Up to 66 months

Secondary (2)

Change in SBP and DBP assessed by ambulatory blood pressure monitoring
Change in SBP and DBP assessed by office blood pressure measurement

Arms and interventions

QCZ484Experimental

QCZ484 administered subcutaneously (SC) Q6M

Drugs: QCZ484

Sites

46 sites in 3 countries

United States 38, Japan 5, Singapore 3